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Prognostic signiﬁcanceAbstract Background: The presence of anaplastic features has been known to correlate with poor
clinical outcome in various pediatric malignancies, including Wilms tumor and medulloblastoma
but not in rhabdomyosarcoma.
Aim: Aim was to study the frequency of anaplasia at presentation in childhood rhabdomyosar-
coma and its relationship to clinical and pathological characteristics as well as to outcome.
Patients and Methods: Anaplasia was retrospectively assessed in 105 consecutive pediatric rhab-
domyosarcoma patients who were registered at the Children’s Cancer Hospital in Egypt (CCHE)
during the period from July 2007 till the end of May 2010.
Results: Anaplasia was diagnosed in 18 patients (17.1%), focal in 10 (9.5%) and diffuse in 8
(7.6%). The distribution of anaplasia was found to be more common in older patients having
ageP 10 years. Also it was more likely to occur in the high risk group and in tumors with unfavor-
able histology (alveolar subtype), and stage IV. The 3-year failure free survival rates for patients
with and without anaplasia were 27.8 ± 10.6% and 53.4 ± 5.8%, respectively (p= 0.014) and
the 3-year overall survival rates were 35.3 ± 11.6% and 61 ± 6%, respectively (p= 0.019).
Conclusions: The frequency of anaplasia in pediatric patients with rhabdomyosarcoma in our study
was 17.1%. The presence of anaplasia had statistically signiﬁcant worse clinical outcome.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rhabdomyosarcoma (RMS) is the fourth most common
pediatric solid tumor with increasing incidence, predominantly
84 I. Sidhom et al.affecting young children. Multimodal treatment has improved
survival signiﬁcantly during the last decades to approximately
70% [1]. The intensity of treatment depends on the estimated
relapse risk, thus treatment is risk adapted. Extent of disease,
primary tumor site, clinical group and histology have been
associated consistently with prognosis [2] and thus have pro-
ven useful for the development of risk-based therapy.
Although the majority of patients achieve a complete remis-
sion (CR) with primary therapy, a substantial number still
experience recurrences with poor prognosis [3,4]. More accu-
rate estimation of prognosis is needed to improve patient strat-
iﬁcation and permit further treatment tailoring according to
relapse risk.
Rhabdomyosarcoma can be divided into several histologic
subsets: embryonal rhabdomyosarcoma, which has embryo-
nal, botryoid, and spindle cell subtypes; alveolar rhab-
domyosarcoma; and pleomorphic rhabdomyosarcoma.
Pleomorphic rhabdomyosarcoma occurs predominantly in
adults aged 30 to 50 years and is rarely seen in children [4].
In adults, pleomorphic rhabdomyosarcoma is associated with
a worse prognosis. In children, the term anaplasia is preferred.
Anaplasia is rare in childhood rhabdomyosarcoma and has
not been included in the International Classiﬁcation of
Rhabdomyosarcoma (ICR). A review of the Soft Tissue
Sarcoma Committee of the Children’s Oncology Group
(COG) suggests that anaplasia might be more common than
previously reported and may impact clinical outcome [5].
The degree of anaplasia was further deﬁned not just by rela-
tive quantity but also apparent clonal expansion of the
anaplastic nuclei in the tumor. Type I tumors as deﬁned by
Kodet included anaplastic cells loosely scattered among non-
anaplastic cells (so called focal anaplasia), and type II tumors
included those with anaplastic cells that were aggregated in
clusters or formed continuous sheets. Despite the suggestion
that anaplasia could signiﬁcantly affect outcome, its relative
rarity and lack of reproducibility on multi-reviewer studies
precluded incorporation of this feature as a morphologic cri-
teria for assessment in the International Classiﬁcation of
Rhabdomyosarcoma [5].
A better understanding of biologic differences and new,
active agents is needed to improve outcome of patients with
unfavorable features at presentation [10].
The aim of this work was to study the frequency of anapla-
sia at presentation in childhood rhabdomyosarcoma and its
relationship to clinical and pathological characteristics as well
as to outcome.
Patients and methods
One-hundred and ﬁve consecutive pediatric patients with
newly diagnosed rhabdomyosarcoma who were registered at
the Children’s Cancer Hospital in Egypt (CCHE) during the
period from July 2007 till end of May 2010 were included in
this study. Their ages ranged from 2 months to 17.7 years.
They included 70 males and 35 females.
All pathological materials were reviewed blindly by two
pathologists for the presence of anaplasia. Cases were cat-
egorized according to the International classiﬁcation of
Childhood Sarcomas [6].
Anaplasia was deﬁned as the presence of multipolar poly-
ploid mitotic ﬁgures with marked nuclear enlargement andhyperchromasia (at least 3 times the size of neighboring nuclei).
Anaplastic cells present in one or a few sharply localized
regions within the primary tumor were categorized as focal ana-
plasia, while those that were aggregated in clusters or formed
continuous sheets were considered as diffuse anaplasia [7].
The presence or absence of anaplasia (diffuse or focal) was
correlated with clinical and pathological variables including
age, sex, primary tumor site, histologic subtype, IRS clinical
group, stage, tumor size, tumor invasiveness and nodal status
as well as to clinical outcome.
Staging and classiﬁcations
Tumors were classiﬁed according to the Intergroup
Rhabdomyosarcoma Study (IRS) pretreatment TNM staging
[8] and grouping system [9]. Imaging and surgery determined
the extent of disease for assignment of IRS Stage and
Group, respectively. Tumors were categorized according to
sites of origin into favorable sites (orbit, non-parameningeal
head and neck, genitourinary other than bladder and prostate)
or unfavorable (extremity, bladder, prostate, parameningeal
sites, retroperitoneum, trunk, other). Histology was deter-
mined as embryonal (including spindle cell and botryoid sub-
types), and non-embryonal histology that included alveolar
subtype and undifferentiated.
Therapy
Patients were treated with risk adapted combined modality
treatment including surgery, multiagent chemotherapy and/
or radiotherapy.
Therapy was assigned based on the IRSG rhabdomyosar-
coma risk group classiﬁcation [10,11]. Patients were classiﬁed
according to the stage, clinical group and histological subtype
into:
a. Low risk group: Included patients with embryonal RMS
or botryoid who had:
- Non-metastatic tumors arising in favorable sites
(stage1), clinical group I, II, or III.
- Non-metastatic tumors in unfavorable sites (stage 2 or
3) that are grossly resected with or without microscopic
residual (clinical group I or II).
b. Intermediate risk group: Included patients with:
- Embryonal RMS or botryoid who had stage 2 or 3 and
clinical group III.
- Alveolar RMS who had stage 1, 2, or 3 and clinical
group I, II, or III.
- Non metastatic Parameningeal primary site regardless
of the histology who had clinical group I, II, or III.
c. High risk group: Included all metastatic patients with
stage 4.
Chemotherapy
Treatment protocol is summarized in Table 1.
Local therapy
A delayed surgery if possible was performed for patients with
clinical group III disease on week 12. No radiotherapy was
Table 1 Chemotherapy protocol of the studied Rhabdomyosarcoma patients.
a. Low risk group
Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13
VAC V V VAC V V VAC V V AC ** ** VA
Weeks 14 15 16 17 18 19 20 21 22 23 24 25 26
V V VA V V VA V V A ** ** VA V
Weeks 27 28 29 30 31 32 33 34 35 36 37 38 39
V VA V V VA V V A ** ** VA V V
Weeks 40 41 42 43 44 45 46 47
VA V V VA V V VA **
Vincristine (V): 1.5 mg/m2 (max. 2 mg) IV push.
Actinomycin (A): 0.045 mg/kg (max. 2.5 mg) IV push.
Cyclophosphamide (C): 1.2 gm/m2 IV infusion over 60 min with hydration and MESNA.
**No chemotherapy and the time of re-evaluation (at weeks 12, 24, 36 and 47 end of therapy).
b. Intermediate and High risk group
Weeks 0 1 2 3 4 5 6 7 8 9 10 11 12
VAC V V VAC V V VAC V V VAC V V VAC**
Weeks 13 14 15 16 17 18 19 20 21 22 23 24 25
– – VC – – VC V V V VAC V V** VAC
Weeks 26 27 28 29 30 31 32 33 34 35 36 37 40
V V VAC – – VAC V V VAC V V VAC **
Vincristine (V): 1.5 mg/m2 IV push.
Actinomycin (A): 1.35 mg/m2 IV push.
Cyclophosphamide (C): 1.5 mg/m2 at weeks 0 and 3 to be increased to 1.8 gm/m2 if tolerated, given IV infusion over 2 h with MESNA and
ﬂuids.
** Time of re-evaluation (at weeks 12, 24, and 40 end of therapy).
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group I. All other patients received radiotherapy following
week 12 except in cases of parameningeal sites with criteria
of meningeal extension, where radiotherapy was given on
day 0.
The gross tumor volume (GTV) was deﬁned as the pre-
treatment visible and for palpable disease detected by physical
examination, operative ﬁndings, CT or MRI including any
involved lymph nodes. For all clinical groups, the clinical
target volume (CTV) was deﬁned by adding one cm safety
margin to GTV. Those who have clinical group III disease
who do not undergo a second look operation may have a sec-
ond CTV deﬁned for a core down boost. The planning tumor
volume (PTV) is created by adding safety margins that deal
with the setup position uncertainties. Clinical group II (stage
I and II) without nodal involvement received 36 Gy, while
those with nodal involvement (N1) received 41.4 Gy. Clinical
group III received 45 Gy if in the orbit and 50.4 Gy in non-or-
bit sites. Patients received radiotherapy to metastatic sites
which can be localized and imaged (i.e. excluding the bone
marrow).
Clinical outcome
Based on previously published data correlating tridimensional
measurements to bi-directional and unidirectional measure-
ments the following response criteria for the primary tumor
will be used:
Complete Response (CR): Complete disappearance of the
tumor conﬁrmed at >4 weeks.
Partial Response (PR): At least 64% decrease in volume
compared to the baseline.Progressive Disease (PD): At least 40% increase in tumor
volume compared to the smallest measurement obtained since
the beginning of therapy.
Stable Disease (SD): Neither sufﬁcient shrinkage to qualify
for PR nor sufﬁcient increase to qualify for PD taking as refer-
ence the smallest disease measurement since the treatment
started.
Statistical analysis
Patients’ data were tabulated and processed using (SPSS) sta-
tistical package (16) for Windows [12]. Qualitative data were
expressed as frequency and percentage, while quantitative data
were expressed as mean ± SD and median. The chi-square test
and Fisher Exact test were used for comparative analysis.
Statistically signiﬁcant level was considered at p 6 0.05.
Survival estimates were calculated using the Kaplan–Meier
method and the standard error of the life-table estimates was
calculated with Greenwood formula. Patients without adverse
events were censored on the date of the last reported contact.
The differences between curves were tested for statistical sig-
niﬁcance using the log rank test [13].
Failure-free survival (FFS)
Failure-free survival (FFS) was deﬁned as the time from the
start of treatment to disease progression, recurrence, or death
as a ﬁrst event.
Overall survival (OS)
Overall survival (OS) was deﬁned as the time from the start of
treatment to death whatever the cause is.
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Patient characteristics
The study included 105 newly diagnosed consecutive RMS
recruited from July 2007 till the end of May 2010. The median
age of diagnosis was 3.6 years (range 2 months–17.7 years)
mean 4.98 ± 4.1. The male to female ratio was 2:1. Fifteen
patients (14.3%) presented with an age 6 1 year, 72 (68.6%)
between 1 and 10 years, and 18 (17.1%)P 10 years. The fol-
low up period ranged 25–66 months with a median of
47.5 months.
Tumor characteristics
The primary site location was favorable in 34 (32.4%) and
unfavorable in 71patients (67.6%). The histological subtype
was embryonal in 88 (83.8%) [sarcoma botryoides in 9
(8.6%) and spindle cell in 20 (19%)], and alveolar in 17
(16.2%) of the tumors.
Anaplasia was diagnosed in 18 patients (17.1%), focal in 10
(9.5%) and diffuse in 8 (7.6%). Twelve patients had embryonal
subtype and six patients were classiﬁed as alveolar. Fig. 1
shows an embryonal rhabdomyosarcoma with diffuse anapla-
sia (Hx and E stain).
The tumor size was Ta in 34 (32.4%), Tb in 63 (60%), and
unknown in 8 (7.6%), while the tumor extension was T1 in 38
(36.2%), T2 in 59 (56.2%) and unknown in 8 (7.6%). Regional
nodal metastasis (N1) occurred in 36 (34.3%), while distant
metastasis (M1) in 18 patients (17.1%). IRSG stage dis-
tribution was found to be: Stage 1 in 28 (26.7%), Stage 2 in
15 (14.3%), Stage 3 in 44 (41.9%) and Stage 4 in 18
(17.1%). Clinical group classiﬁcation was I in 9 (8.6%), II inFigure 1 Embryonalrhabdomyosarcoma showing diffuse ana-
plasia: enlarged nuclei, prominent nucleoli and abnormal mitoses
(arrows); Hx& E stain (100·).4 (3.8%), III in 74 (70.5%) and IV in 18 (17.1%). Twenty
patients (19%) were categorized as low risk, 67 (63.8%) as
intermediate risk, and 18 (17.1%) as high risk. For the 18
patients who initially presented with distant metastasis, the
sites of spread were pulmonary in six, bone in three, bone mar-
row combined with bone in two, pulmonary combined with
bone, distant nodes or bone marrow in seven patients.
Outcome
Thirty-one patients had progressive disease, two were refrac-
tory and 17 patients died of toxicity. Seven patients lost follow
up in CR and 48 patients were alive in continuous complete
remission. The 3-year FFS was 48.6 ± 5.3%, while the 3-year
OS was 56.1 ± 5.6% (Fig. 2).
Relation of anaplasia to outcome
Of the eighteen patients having tumors showing anaplasia, six
(33.3%) were alive in CR, while 2 (11.1%) were refractory, 7
(38.9%) had progressive disease and 3 (16.7%) died of sepsis
(Table 2).
There was a statistically signiﬁcant association between
the presence of anaplasia and clinical outcome (p= 0.003).
The 3-year FFS rates for patients with and without anaplasia
were 27.8 ± 10.6% and 53.4 ± 5.8%, respectively (p= 0.014)
and the 3-year overall survival rates were 35.3 ± 11.6% and
61 ± 6%, respectively (p= 0.019) (Fig. 3).
Relation of anaplasia to clinical and pathological variables
The presence or absence of anaplasia was correlated to age,
sex, primary tumor site, histologic subtype, IRS clinical group,
stage, tumor size, tumor invasiveness, lymph node involvement
and risk groups (Table 3).Figure 2 Failure free survival and overall survival of the studied
rhabdomyosarcoma patients.
Table 2 Relation of anaplasia to outcome.
Anaplasia
status
Alive in
CR
NR PD Died of
sepsis
p-
value
Anaplasia
(n= 18)
6
(33.3%)
2
(11.1%)
7
(38.9%)
3
(16.7%)
0.003
No anaplasia
(n= 87)
60
(69%)
0 24
(27.6%)
3 (3.4%)
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ageP 10 years, in high risk group and in tumors with unfavor-
able histology (non-embryonal), and stage IV. However, these
differences were statistically not signiﬁcant.
Relation of anaplasia to surgical respectability
Of the eighteen patients with anaplasia, 3 (16.6%) patients had
upfront surgery but with gross residual (R2) and 3 (16.6%)
patients had delayed surgery at the time of local control (one
complete resection R0, one microscopic residual R1 & one
gross residual R2).
On the other hand, 20/87 (23%) patients without anaplasia
had upfront surgery (9 R0, 5 R1, 6 R2), while 15 (17%)
patients had delayed surgery at time of local control (10 R0,
3 R1 and 2 R2). Surgical resection with gross or microscopic
residual was followed by radiotherapy.
Discussion
The presence of anaplastic features such as increased nuclear
size, marked cytological pleomorphism, numerous mitoses,
and apoptotic bodies has been known to correlate with poorFigure 3 Failure free survival and overall survclinical outcome in various pediatric malignancies, including
Wilms tumor [14,15] and medulloblastoma [16,17].
Palmer ﬁrst noted that the anaplastic cellular pattern he
originally described with Beckwith in Wilms tumor was also
present in rhabdomyosarcoma and that this subtype carried
a similarly poor prognosis [5]. Few studies suggested that ana-
plasia in RMS could signiﬁcantly affect outcome, however, it
has not been included in the International Classiﬁcation of
Rhabdomyosarcoma (ICR) due to its apparent relative rarity.
Kodet et al. identiﬁed anaplastic cells in 3% among cases of
rhabdomyosarcoma patients registered in the ﬁrst 3 Intergroup
Rhabdomyosarcoma Studies (IRS I-III) [18]. In a study by
Qualman et al. (2008) [5], the soft tissue sarcoma committee
of the Children’s Oncology Group reported a signiﬁcantly
higher prevalence of focal or diffuse anaplasia in childhood
rhabdomyosarcoma than previously reported in other studies.
Anaplasia was noted in 13% of pathologic specimens of child-
hood rhabdomyosarcoma, focal in 7% and diffuse in 6%. In
our study, anaplasia was diagnosed in 17.1% of the patients,
focal in 9.5% and diffuse in 7.6%.
Furthermore, Qualman et al. observed that patients with
anaplasia were more likely to have tumors in favorable sites,
group IV disease, and tumor size of >5 cm. Anaplasia was less
commonly observed in younger patients and in those with
stage II, III, or clinical group III disease [5]. Similarly in this
study, the distribution of anaplasia was found to be more com-
mon in older patients having ageP 10 years. Also it was more
likely to occur in the high risk group and in tumors with
unfavorable histology (alveolar subtype), and stage IV.
Anaplastic histology is the single most important histologic
predictor of response and survival in patients with Wilms
tumor. It is most consistently associated with poor prognosisival in relation to the presence of anaplasia.
Table 3 Clinical and pathological features in relation to the
presence or absence of diffuse or focal anaplasia.
Anaplasia p-
value
None
(n= 87)
Anaplasia
(n= 18)
Age, years 0.09
61 year 14 (16.1%) 1 (5.6%)
>1 and <10 years 61 (70.1%) 11 (61.1%)
P10 years 12 (13.8%) 6 (33.3%)
Sex 1
Male 58 (66.7%) 12 (66.6%)
Female 29 (33.3%) 6 (33.3%)
Clinical group 0.14
I 9 (10.4%) 0
II 4 (4.6%) 0
III 62 (71.3%) 12 (66.6%)
IV 12 (13.8%) 6 (33.3%)
Stage 0.18
1 25 (28.7%) 3 (16.7%)
2 14 (16.1%) 1 (5.6%)
3 36 (41.4%) 8 (44.4%)
4 12 (13.8%) 6 (33.3%)
Primary site 0.28
Favorable 25 (28.7%) 7 (38.9%)
Unfavorable 62 (71.3%) 11 (61.1%)
Histology 0.04
Embryonal 76 (87.4%) 12 (66.6%)
Non Embryonal 11 (12.6%) 6 (33.3%)
Tumor invasiveness 0.8
T1 30 (34.5%) 8 (44.4%)
T2 50 (57.5%) 9 (50%)
Unknown 7 (8%) 1 (5.6%)
Lymph node
involvement
0.27
N0 45 (51.7%) 8 (44.4%)
N1 27 (31%) 9 (50%)
Unknown 15 (17.2%) 1 (5.6%)
Tumor size, cm 0.77
65 28 (32.2%) 6 (33.3%)
>5 53 (60.9%) 10 (55.6%)
Unknown 6 (6.9%) 2 (11.1%)
Risk 0.08
Low 19 (21.8%) 1 (5.6%)
Intermediate 56 (64.4%) 11 (61.1%)
High 12 (13.8%) 6 (33.3%)
88 I. Sidhom et al.when it is diffusely distributed and when identiﬁed at advanced
stages. Focal anaplasia does not confer a poor prognosis, while
diffuse anaplasia does [15,19]. In medulloblastomas, a study by
the United Kingdom Children’s Cancer Study Group demon-
strated that children with anaplastic variant had signiﬁcant
worse event free survival than children with classic medul-
loblastomas [20]. On the other hand, another study reported
that the group of patients with either moderate or severely
anaplastic medulloblastomas showed only a trend toward
shorter survival (p= 0.11), while severe anaplasia alone had
signiﬁcant worse clinical outcome (p= 0.002) [21].As regards rhabdomyosarcoma, Kodet et al. reported that
rhabdomyosarcoma patients with diffuse anaplasia had a
worse clinical outcome [18]. In contrast, Qualman et al.
reported that the presence of anaplasia regardless of its dis-
tribution (focal or diffuse), negatively inﬂuenced the failure-
free survival rate on univariate analysis (63% vs 77% at
5 years) and overall survival (68% vs 82% at 5 years) rates
in patients with embryonal rhabdomyosarcoma [5].
In this study, the presence of anaplasia had statistically sig-
niﬁcant negative impact on the 3-year FFS and OS rates being
27.8 ± 10.6% and 35.3 ± 11.6%, respectively vs.
53.4 ± 5.8%, and 61 ± 6%, for patients without anaplasia,
respectively. The effect of diffuse versus focal anaplasia on sur-
vival cannot be assessed due to small number of patients in
each group, however, percentage of patients with refractory
and progressive disease were equal in both groups (4/8 and
5/10 patients with diffuse and focal anaplasia, respectively).
In conclusion, the current study demonstrated that anapla-
sia was present in 17.1% of the patients. Anaplasia was found
in 6 (33%) of cases above 10 years, 6 (33%) cases were high
risk, and 6 (33%) cases were of non-embryonal histology.
Despite that most of correlations to anaplasia were found to
be insigniﬁcant, it was found to be signiﬁcant when correlated
to survival.
Based on the small number of patients included in our
study, further studies are needed to assess whether anaplasia
is an independent prognostic factor in pediatric patients with
rhabdomyosarcoma or not.
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